Mannes G P, van der Bij W, de Boer W J
Department of Pulmonary Diseases, University Hospital, Groningen, The Netherlands.
J Heart Lung Transplant. 1995 Jul-Aug;14(4):781-4.
Opportunistic fungal infections are an important cause of morbidity and mortality in solid organ transplant recipients. Conventional therapy with amphotericin B is often restricted by toxicity. However, side effects and toxicity of liposomal amphotericin B are reported to be limited.
Three lung transplant recipients with proven infections with Aspergillus fumigatus were treated with liposomal amphotericin B.
Therapy with liposomal amphotericin B in our patients showed more side effects and (nephro)toxicity than suggested by previous reports. However, it did not result in cessation of treatment prematurely, and patients were able to complete the antifungal therapy with good clinical success.
Treatment with liposomal amphotericin B represents an advance from conventional amphotericin B therapy.
机会性真菌感染是实体器官移植受者发病和死亡的重要原因。两性霉素B的传统疗法常受毒性限制。然而，据报道脂质体两性霉素B的副作用和毒性有限。
对3例确诊为烟曲霉感染的肺移植受者采用脂质体两性霉素B治疗。
我们的患者接受脂质体两性霉素B治疗时出现的副作用和（肾）毒性比先前报道的更多。然而，这并未导致过早停药，患者能够完成抗真菌治疗并取得良好的临床疗效。
脂质体两性霉素B治疗是对传统两性霉素B治疗的一种改进。
